Kanvas Biosciences Raises $48M Series A for Microbiome Therapies
Kanvas Biosciences, a South San Francisco-based developer of live biotherapeutics modulating host-microbiome interactions for cancer and gut disorders, has raised $48M in Series A funding co-led by DCVC and Lions Capital. The company employs HiPR-FISH spatial mapping technology to visualize immune-modulating microbes in situ. The capital brings total funding to $78M and will advance Phase 1 trials of KAN-001 for immunotherapy-resistant cancers and KAN-004 for checkpoint-induced colitis, while scaling anaerobic co-culture manufacturing (ACT™).
FDA Approvals Ignite LBP Momentum
This raise aligns with recent FDA nods for live biotherapeutics like Vowst and Rebyota, validating the modality beyond C. difficile infections (per PMC article). Competitors such as Seres Therapeutics commercialize approved products for recurrent infections, while Vedanta Biosciences advances consortia for immune modulation. Kanvas stands out by integrating spatial biology for precise host-microbe insights, targeting oncology gaps unmet by FMT-derived approaches.
Immunotherapy Fails 90% of Patients
Up to 90% of solid tumor patients do not fully respond to immune checkpoint inhibitors, limiting a key cancer treatment (company posts). Current microbiome interventions like fecal microbiota transplants suffer from donor variability and scalability issues. Oncology patients also face immune-related adverse events like colitis, affecting treatment adherence.
Spatial Mapping Unlocks Precise Consortia
Kanvas' HiPR-FISH technology simultaneously images host transcripts and microbial taxonomy at single-cell resolution, outperforming metagenomics in low-biomass samples (Nature publication via company). This enables isolation of functional strains from patient-derived 'super donor' microbiomes, as with KAN-001 partnered with MD Anderson Cancer Center. Unlike synthetic biology peers like Synlogic Therapeutics, Kanvas focuses on natural consortia exceeding 100 strains, manufactured scalably via ACT™.
As Jason Pontin of DCVC noted:
"Creating a brand new microscope capable of collecting spatial biology data at the unprecedented resolution needed to illuminate host-microbiome interactions."
KAN-004, now 25% through Phase 1, builds on prior FMT data showing microbiome engraftment and response restoration (BusinessWire).
DCVC Follow-On Signals Deep Tech Bet
DCVC, a repeat investor from seed rounds with exits like Recursion Pharmaceuticals IPO, brings conviction in spatial platforms (DCVC site). The Bill & Melinda Gates Foundation's participation underscores global health potential for KAN-007 against environmental enteric dysfunction. Lions Capital and Pangaea Ventures add biotech manufacturing expertise, positioning Kanvas for pharma partnerships.
Microbiome Market Scales to Billions
The microbiome therapeutics market stands at $212.1M in 2024, projected to reach $3.2B by 2034 at 31.1% CAGR (GMI). Alternative forecasts see $21.5B by 2030 amid GI disorder prevalence (GlobeNewswire). Trends favor immuno-oncology expansion, where Kanvas' full-stack—from HiPR imaging to GMP services—addresses CMC hurdles.
Quake Bolsters Scientific Leadership
Stephen Quake, D.Phil., joined the board post-raise, bringing expertise in spatial biology (company announcement). Co-founder CEO Matthew Cheng, a former physician, leads alongside CTO Hao S. and Iwijn De Vlaminck, with MD Anderson and Gates partnerships validating domain strength.
Phase 1 Trials Advance Pipeline
Kanvas plans First Patient In for KAN-001 Phase 1 in NSCLC non-responders, following KAN-004 dosing at CRCHUM (Endpoints News). A new GMP suite in South San Francisco supports IND readiness, with slots opening Q3 2026.